Novo Nordisk A/S Sponsored ADR (NVO)
Summary
NVO Chart
Novo Nordisk's Moat Is Deeper Than You Think
Novo Nordisk holds 72% international and 50%+ U.S. market share in GLP-1 treatments, serving 46 million patients globally. Obesity drug sales surged 65% YoY in Q1-FY25, driving total revenue growth of 18% and free cash flow of $1.38 billion. The company projects FY25 free cash flow between $8.14–$9.59 billion, supported by 48.43% EBIT margins and expanding manufacturing capacity.
Novo Nordisk Has So Much Room To Go
Novo Nordisk's Q1 2025 results were solid, but FY guidance was cut, suggesting a longer recovery. Large growth potential exists, with 85% of diabetes patients undertreated and obesity treatments under 1% market penetration. The company is investing heavily in expanding manufacturing capacity ($9B+ capex) to meet rising GLP-1 demand, while risks from US drug price cuts seem limited.
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
Wegovy and Ozempic drive 66% of NVO's Q1 revenues - investors eye Q2 sales ahead of results on Aug. 6.
Novo Nordisk A/S Sponsored ADR Dividends
| NVO In 2 months Estimated | Other | $1.1 Per Share |
| NVO 3 months ago Paid | Other | $1.1 Per Share |
| NVO 11 months ago Paid | Other | $0.52 Per Share |
| NVO 22 Mar 2024 Paid | Other | $0.93 Per Share |
| NVO 18 Aug 2023 Paid | Other | $0.44 Per Share |
| NVO 24 Mar 2023 Paid | Other | $0.59 Per Share |
Novo Nordisk A/S Sponsored ADR Earnings
| 6 Aug 2025 (In 2 weeks) Date | | 5.98 Cons. EPS | - EPS |
| 7 May 2025 Date | | 0.92 Cons. EPS | 6.53 EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 5 Feb 2025 Date | | 6.12 Cons. EPS | 6.34 EPS |
| 6 Nov 2024 Date | | 0.88 Cons. EPS | 0.9 EPS |
| NVO In 2 months Estimated | Other | $1.1 Per Share |
| NVO 3 months ago Paid | Other | $1.1 Per Share |
| NVO 11 months ago Paid | Other | $0.52 Per Share |
| NVO 22 Mar 2024 Paid | Other | $0.93 Per Share |
| NVO 18 Aug 2023 Paid | Other | $0.44 Per Share |
| NVO 24 Mar 2023 Paid | Other | $0.59 Per Share |
| 6 Aug 2025 (In 2 weeks) Date | | 5.98 Cons. EPS | - EPS |
| 7 May 2025 Date | | 0.92 Cons. EPS | 6.53 EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 5 Feb 2025 Date | | 6.12 Cons. EPS | 6.34 EPS |
| 6 Nov 2024 Date | | 0.88 Cons. EPS | 0.9 EPS |
Novo Nordisk A/S Sponsored ADR (NVO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Novo Nordisk A/S Sponsored ADR ever had a stock split?
Novo Nordisk A/S Sponsored ADR Profile
| Drug Manufacturers - General Industry | Healthcare Sector | Lars Fruergaard Jorgensen CEO | NYSE Exchange | 670100205 Cusip |
| DK Country | 77,406 Employees | 31 Mar 2025 Last Dividend | 20 Sep 2023 Last Split | - IPO Date |
Overview
Novo Nordisk A/S is an established global pharmaceutical company with a heritage dating back to 1923. With its headquarters in Bagsvaerd, Denmark, the company has a widespread operational reach across Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and other international markets. Novo Nordisk is committed to discovering and developing innovative pharmaceutical products, focusing primarily on Diabetes and Obesity Care, and Rare Disease. The company has carved a niche for itself by not just being a manufacturer but also engaging in the research and development of new pharmaceutical products, ensuring they provide contemporary and efficient solutions to the healthcare challenges of today.
Products and Services
Novo Nordisk A/S offers a comprehensive range of healthcare products and solutions aimed at addressing some of the most challenging diseases. With a focus on quality and innovation, their offerings encompass:
- Diabetes and Obesity Care: This segment includes products specifically designed to manage diabetes and obesity, along with related cardiovascular conditions and other emerging therapeutic areas. The company’s commitment to combating diabetes and obesity is reflected in its continuous pursuit of safer and more effective treatments.
- Rare Disease: Novo Nordisk takes a targeted approach to rare diseases, focusing on rare blood disorders, rare endocrine disorders, and providing hormone replacement therapy. These specialized treatments are developed with the aim of addressing medical needs that are often underserved, demonstrating the company's dedication to all patients, regardless of the rarity of their condition.
- Insulin Pens: The company produces a variety of insulin pens that are designed for ease of use, ensuring that patients can manage their condition with confidence and precision. These devices are a testament to Novo Nordisk’s focus on patient-centric innovations.
- Growth Hormone Pens: These pens are part of the portfolio intended for patients requiring growth hormone therapy. They simplify the administration process, making treatment more accessible and manageable for patients.
- Injection Needles: To complement their insulin and growth hormone pens, Novo Nordisk also supplies high-quality injection needles, designed for minimal discomfort and optimal medication delivery.
- Smart Solutions for Diabetes: Innovating beyond conventional treatments, Novo Nordisk offers smart insulin pens and Dose Check, an insulin dose guidance application. These smart solutions enhance the treatment experience by integrating advanced technology with patient care, facilitating better management of diabetes.
Through a collaboration agreement with Aspen Pharmaceuticals, Novo Nordisk also ensures the production of insulin products, highlighting their commitment to making essential medications accessible. The company's enduring legacy and forward-looking approach have positioned it as a key player in the global pharmaceutical industry, dedicated to improving the lives of patients worldwide.
Contact Information
